These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 33602823)

  • 1. Activation of NF-κB and p300/CBP potentiates cancer chemoimmunotherapy through induction of MHC-I antigen presentation.
    Zhou Y; Bastian IN; Long MD; Dow M; Li W; Liu T; Ngu RK; Antonucci L; Huang JY; Phung QT; Zhao XH; Banerjee S; Lin XJ; Wang H; Dang B; Choi S; Karin D; Su H; Ellisman MH; Jamieson C; Bosenberg M; Cheng Z; Haybaeck J; Kenner L; Fisch KM; Bourgon R; Hernandez G; Lill JR; Liu S; Carter H; Mellman I; Karin M; Shalapour S
    Proc Natl Acad Sci U S A; 2021 Feb; 118(8):. PubMed ID: 33602823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of NKG2D ligand expression on tumor cells by CD8
    Hu J; Xia X; Gorlick R; Li S
    Oncogene; 2019 Dec; 38(49):7433-7446. PubMed ID: 31427736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p300/CBP inhibition enhances the efficacy of programmed death-ligand 1 blockade treatment in prostate cancer.
    Liu J; He D; Cheng L; Huang C; Zhang Y; Rao X; Kong Y; Li C; Zhang Z; Liu J; Jones K; Napier D; Lee EY; Wang C; Liu X
    Oncogene; 2020 May; 39(19):3939-3951. PubMed ID: 32203167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies.
    Minnar CM; Chariou PL; Horn LA; Hicks KC; Palena C; Schlom J; Gameiro SR
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequent Loss of IRF2 in Cancers Leads to Immune Evasion through Decreased MHC Class I Antigen Presentation and Increased PD-L1 Expression.
    Kriegsman BA; Vangala P; Chen BJ; Meraner P; Brass AL; Garber M; Rock KL
    J Immunol; 2019 Oct; 203(7):1999-2010. PubMed ID: 31471524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the MHC-I endosomal-lysosomal trafficking pathway in cancer: From mechanism to immunotherapy.
    Ye D; Zhou S; Dai X; Xu H; Tang Q; Huang H; Bi F
    Biochim Biophys Acta Rev Cancer; 2024 Sep; 1879(5):189161. PubMed ID: 39096977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
    Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hippo-signaling-controlled MHC class I antigen processing and presentation pathway potentiates antitumor immunity.
    Peng L; Zhou L; Li H; Zhang X; Li S; Wang K; Yang M; Ma X; Zhang D; Xiang S; Duan Y; Wang T; Sun C; Wang C; Lu D; Qian M; Wang Z
    Cell Rep; 2024 Apr; 43(4):114003. PubMed ID: 38527062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel IFNα-induced long noncoding RNA negatively regulates immunosuppression by interrupting H3K27 acetylation in head and neck squamous cell carcinoma.
    Ma H; Chang H; Yang W; Lu Y; Hu J; Jin S
    Mol Cancer; 2020 Jan; 19(1):4. PubMed ID: 31907020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MHC class I-independent activation of virtual memory CD8 T cells induced by chemotherapeutic agent-treated cancer cells.
    Wang X; Waschke BC; Woolaver RA; Chen SMY; Chen Z; Wang JH
    Cell Mol Immunol; 2021 Mar; 18(3):723-734. PubMed ID: 32427883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy.
    Briere D; Sudhakar N; Woods DM; Hallin J; Engstrom LD; Aranda R; Chiang H; Sodré AL; Olson P; Weber JS; Christensen JG
    Cancer Immunol Immunother; 2018 Mar; 67(3):381-392. PubMed ID: 29124315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CBP/p300 acetyltransferases regulate the expression of NKG2D ligands on tumor cells.
    Sauer M; Schuldner M; Hoffmann N; Cetintas A; Reiners KS; Shatnyeva O; Hallek M; Hansen HP; Gasser S; von Strandmann EP
    Oncogene; 2017 Feb; 36(7):933-941. PubMed ID: 27477692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours.
    Lasko LM; Jakob CG; Edalji RP; Qiu W; Montgomery D; Digiammarino EL; Hansen TM; Risi RM; Frey R; Manaves V; Shaw B; Algire M; Hessler P; Lam LT; Uziel T; Faivre E; Ferguson D; Buchanan FG; Martin RL; Torrent M; Chiang GG; Karukurichi K; Langston JW; Weinert BT; Choudhary C; de Vries P; Van Drie JH; McElligott D; Kesicki E; Marmorstein R; Sun C; Cole PA; Rosenberg SH; Michaelides MR; Lai A; Bromberg KD
    Nature; 2017 Oct; 550(7674):128-132. PubMed ID: 28953875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. APE1 facilitates PD-L1-mediated progression of laryngeal and hypopharyngeal squamous cell carcinoma.
    Wang J; Lun L; Jiang X; Wang Y; Li X; Du G; Wang J
    Int Immunopharmacol; 2021 Aug; 97():107675. PubMed ID: 33964809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer.
    Burr ML; Sparbier CE; Chan KL; Chan YC; Kersbergen A; Lam EYN; Azidis-Yates E; Vassiliadis D; Bell CC; Gilan O; Jackson S; Tan L; Wong SQ; Hollizeck S; Michalak EM; Siddle HV; McCabe MT; Prinjha RK; Guerra GR; Solomon BJ; Sandhu S; Dawson SJ; Beavis PA; Tothill RW; Cullinane C; Lehner PJ; Sutherland KD; Dawson MA
    Cancer Cell; 2019 Oct; 36(4):385-401.e8. PubMed ID: 31564637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NF-κB and Its Role in Checkpoint Control.
    Betzler AC; Theodoraki MN; Schuler PJ; Döscher J; Laban S; Hoffmann TK; Brunner C
    Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32486375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer cell-intrinsic expression of MHC II in lung cancer cell lines is actively restricted by MEK/ERK signaling and epigenetic mechanisms.
    Neuwelt AJ; Kimball AK; Johnson AM; Arnold BW; Bullock BL; Kaspar RE; Kleczko EK; Kwak JW; Wu MH; Heasley LE; Doebele RC; Li HY; Nemenoff RA; Clambey ET
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32312906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gut-derived lipopolysaccharide remodels tumoral microenvironment and synergizes with PD-L1 checkpoint blockade via TLR4/MyD88/AKT/NF-κB pathway in pancreatic cancer.
    Yin H; Pu N; Chen Q; Zhang J; Zhao G; Xu X; Wang D; Kuang T; Jin D; Lou W; Wu W
    Cell Death Dis; 2021 Oct; 12(11):1033. PubMed ID: 34718325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IFN-γ treatment protocol for MHC-I
    Stifter K; Krieger J; Ruths L; Gout J; Mulaw M; Lechel A; Kleger A; Seufferlein T; Wagner M; Schirmbeck R
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32868392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.